EBMT 2022 | Emerging therapeutic approaches for TKI-resistant CML
Guillermo Ortí
• 21 Mar 2022
Despite the benefit brought by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still progress on TKIs or are intolerant to these drugs. In this video, Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of current and emerging treatment approaches for this patient population. Stem cell transplantation (SCT) remains the best option for patients who can achieve a response prior to transplant, and several immunotherapeutic approaches including CAR-T therapy are also currently being evaluated. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
